Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

PURPOSE: Dolutegravir (DTG) is primarily metabolized by UGT1A1 with CYP3A as a minor route. Carbamazepine (CBZ) is a potent inducer of these enzymes; thus, the effect of oral extended-release CBZ on DTG pharmacokinetics (PK) was evaluated to provide dose recommendation when co-administered. METHODS:...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Clin Pharmacol
Asıl Yazarlar: Song, Ivy, Weller, Steve, Patel, Juhin, Borland, Julie, Wynne, Brian, Choukour, Mike, Jerva, Fred, Piscitelli, Stephen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2016
Konular:
Clinical Trial
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4865535/
https://ncbi.nlm.nih.gov/pubmed/26898568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-016-2020-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller